TRCT
KLDO

Tower Research Capital (TRC)’s Kaleido Biosciences, Inc. Common Stock KLDO Stock Holding History

Tower Research Capital (TRC)’s Portfolio KLDO Stock Details KLDO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-9,407
Closed -$16K – 7061
2022
Q1 		$16K Buy
9,407
+5,065
+117% +$9.04K ﹤0.01% 3786
2021
Q4 		$10K Buy
4,342
+2,576
+146% +$10.5K ﹤0.01% 4658
2021
Q3 		$10K Sell
1,766
-2,249
-56% -$14K ﹤0.01% 4390
2021
Q2 		$30K Sell
4,015
-2,297
-36% -$16.3K ﹤0.01% 3507
2021
Q1 		$51K Sell
6,312
-3,759
-37% -$40.9K ﹤0.01% 3117
2020
Q4 		$92K Sell
10,071
-1,558
-13% -$12.8K ﹤0.01% 2431
2020
Q3 		$129K Buy
11,629
+9,068
+354% +$62.8K ﹤0.01% 2940
2020
Q2 		$19K Buy
+2,561
New +$17.2K ﹤0.01% 3718
2020
Q1 		– Sell
-8,772
Closed -$44K – 4263
2019
Q4 		$44K Buy
+8,772
New +$55.7K ﹤0.01% 1429
2019
Q3 		– Sell
-4,821
Closed -$56K – 4703
2019
Q2 		$56K Buy
+4,821
New +$70.2K ﹤0.01% 1526

Other funds holding KLDO

AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Tower Research Capital (TRC)'s KLDO Position: Q2 2022 in Review

Tower Research Capital (TRC) sold out of Kaleido Biosciences, Inc. Common Stock (KLDO) in Q2 2022, closing a stake of 9,407 shares — an estimated $16K sold.

Tower Research Capital (TRC) first reported a position in KLDO in Q2 2019 and held it in 10 quarters. The position peaked at $129K in Q3 2020. 3 funds tracked by Wall St. Rank hold KLDO as of Q2 2022.

  • Tower Research Capital (TRC) reported no remaining Kaleido Biosciences, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
  • Tower Research Capital (TRC) sold 9,407 Kaleido Biosciences, Inc. Common Stock shares in Q2 2022, an estimated $16K.
  • Tower Research Capital (TRC) first reported a position in Kaleido Biosciences, Inc. Common Stock in Q2 2019 and held it in 10 quarters.
  • Tower Research Capital (TRC)'s Kaleido Biosciences, Inc. Common Stock position peaked at $129K in Q3 2020.
  • 3 funds tracked by Wall St. Rank held Kaleido Biosciences, Inc. Common Stock as of Q2 2022.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2022, filed 15 Aug 2022.